Share

October 2016; 3 (5) Clinical/Scientific NotesOpen Access

Lymphopenia in treatment-naive relapsing multiple sclerosis

Zhi Wei Lim, Elliot Elwood, Hammad Naveed, Ian Galea
First published August 12, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000275
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1438

Share

Article Information

vol. 3 no. 5 e275
DOI: 
https://doi.org/10.1212/NXI.0000000000000275
PubMed: 
27559542
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 20, 2015
  • Accepted in final form July 11, 2016
  • First Published August 12, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Zhi Wei Lim, BM BS,
    2. Elliot Elwood, BM BS,
    3. Hammad Naveed, MSc and
    4. Ian Galea, PhD
  1. Zhi Wei Lim, BM BS,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Elliot Elwood, BM BS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Hammad Naveed, MSc and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Ian Galea, PhD
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Teva-UK (meeting expenses)

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Evgen, Merck Serono, Spire

    Research Support, Government Entities:

    1. Engineering and Physical Sciences Research Council UK, Medical Research Council UK

    Research Support, Academic Entities:

    1. Wessex Medical Research, NIHR Clinical Research Network Wessex, Royal College of Surgeons of Edinburgh, University of Southampton

    Research Support, Foundations and Societies:

    1. MS Society, Association of British Neurologists, Smile4Wessex

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From Clinical Neurosciences, Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, UK.
  1. Correspondence to Dr. Galea: I.Galea{at}soton.ac.uk
View Full Text

Article usage

Article usage: August 2016 to August 2023

AbstractFullPdfSource
Aug 20161385061Highwire
Aug 201607017pmc
Sep 201610517440Highwire
Sep 201605522pmc
Oct 20161483840Highwire
Oct 20160375pmc
Nov 2016151311Highwire
Nov 20160408pmc
Dec 2016111315Highwire
Dec 20160211pmc
Jan 2017181816Highwire
Jan 20170266pmc
Feb 201791511Highwire
Feb 20170314pmc
Mar 201716208Highwire
Mar 20170499pmc
Apr 20175185Highwire
Apr 201732628pmc
May 201763312Highwire
May 201754349pmc
Jun 201762414Highwire
Jun 201713138pmc
Jul 20175216Highwire
Jul 201723337pmc
Aug 201733012Highwire
Aug 201754246pmc
Sep 201761021Highwire
Sep 201752833pmc
Oct 201792318Highwire
Oct 201722425pmc
Nov 2017113316Highwire
Nov 201794049pmc
Dec 201701810Highwire
Jan 201883412Highwire
Feb 20183398Highwire
Mar 20183526Highwire
Apr 201814912Highwire
Apr 201814244pmc
May 201833415Highwire
Jun 20182685Highwire
Jun 201885756pmc
Jul 20183865Highwire
Aug 201846111Highwire
Aug 201863435pmc
Sep 20183457Highwire
Oct 20185684Highwire
Nov 20183829Highwire
Dec 2018111335Highwire
Jan 20191210413Highwire
Feb 2019611212Highwire
Mar 201992197Highwire
Apr 2019924119Highwire
May 20191120525Highwire
Jun 2019716614Highwire
Jul 201922248Highwire
Aug 2019340512Highwire
Sep 201953174Highwire
Oct 2019633110Highwire
Nov 2019323915Highwire
Dec 201941425Highwire
Jan 202004913Highwire
Feb 20205456Highwire
Mar 20203399Highwire
Apr 20201218Highwire
May 20202267Highwire
Jun 202033213Highwire
Jul 20200212Highwire
Aug 20201226Highwire
Sep 20209537Highwire
Oct 20201245Highwire
Nov 20200214Highwire
Dec 20203294Highwire
Jan 20212287Highwire
Feb 20210289Highwire
Mar 20211184Highwire
Apr 20212402Highwire
May 20214393Highwire
Jun 20211302Highwire
Jul 202112210Highwire
Aug 202143313Highwire
Sep 20210226Highwire
Oct 202133824Highwire
Nov 202123319Highwire
Dec 20210666Highwire
Jan 20221374Highwire
Feb 20224252Highwire
Mar 20221263Highwire
Apr 20220292Highwire
May 202223510Highwire
Jun 20223314Highwire
Jul 20220192Highwire
Aug 20223355Highwire
Sep 20220359Highwire
Oct 202203712Highwire
Nov 202226521Highwire
Dec 202242610Highwire
Jan 202324517Highwire
Feb 20230347Highwire
Mar 20231307Highwire
Apr 20233148Highwire
May 202301513Highwire
Jun 202304017Highwire
Jul 202302518Highwire
Aug 20230167Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles